卢森堡奥密克戎时期疫苗对重症COVID-19结局的高效性及人群可预防分数:一项全国性回顾性危险因素分析
卢森堡2022年奥密克戎流行期间开展全国性回顾性危险因素分析,链接≥20岁居民SARS-CoV-2病例与疫苗接种、住院和死亡数据。完成基础免疫及加强针对住院的疫苗有效性分别为38.8%、62.1%和71.6%,对死亡的疫苗有效性分别为49.5%、69.0%和76.2%;既往感染与住院或死亡风险降低无关。疫苗接种使人群死亡率降低55.8%、住院减少49.1%。
要点
- 完成基础免疫及加强针对住院的疫苗有效性分别为38.8%、62.1%和71.6%。
- 完成基础免疫及加强针对死亡的疫苗有效性分别为49.5%、69.0%和76.2%。
- 既往感染与住院或死亡风险降低无关。
核心结论
- 完成疫苗接种和加强针可预防住院和死亡,但既往感染无此保护作用。
- 卢森堡疫苗接种规划在人群层面大幅降低了SARS-CoV-2相关死亡和住院。
研究设计与样本
- 全国性回顾性危险因素分析,链接≥20岁居民报告SARS-CoV-2病例与疫苗接种数据及SARS-CoV-2相关住院和死亡数据。
- 病例随访至阳性检测后第14天(住院)和第28天(死亡),采用比例Cox回归调整既往感染、年龄、性别和养老院居住情况。
主要发现
- 2021年12月至2023年3月共记录187143例SARS-CoV-2病例,其中住院1728例(0.93%)、死亡611例(0.33%)。
- 重症结局风险随年龄增加,男性及养老院居住者风险更高。
- 与未接种成年人相比,完成基础免疫、1剂加强针和2剂加强针对住院的疫苗有效性分别为38.8%(95%CI:28.1%-47.8%)、62.1%(95%CI:57.0%-66.7%)和71.6%(95%CI:66.7%-76.2%)。
- 与未接种成年人相比,完成基础免疫、1剂加强针和2剂加强针对死亡的疫苗有效性分别为49.5%(95%CI:30.8%-63.3%)、69.0%(95%CI:61.2%-75.3%)和76.2%(95%CI:68.4%-82.2%)。
- 既往感染与住院或死亡风险降低无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Luxembourg experienced major consecutive SARS-CoV-2 infection waves due to Omicron variants during 2022 while having achieved a high vaccination coverage in 2021. We investigated the risk factors associated to severe outcomes (i.e., hospitalisation, deaths) and estimated vaccine effectiveness (VE) as well as the role of immunity conferred by prior infections against severe outcomes in adults. METHODS: We linked reported SARS-CoV-2 cases among residents aged ≥ 20 years with vaccination data and SARS-CoV-2 related hospitalisations and deaths. Cases were followed-up until day 14 for COVID-19 related hospital admission and up to day 28 for mortality after a positive test. We analysed the association between the vaccination status and severe forms using proportional Cox regression, adjusting for previous infection, age, sex and nursing homes residency. VE was measured as 1-adjusted hazard ratio of vaccinated vs unvaccinated individuals. The population preventable fraction was computed using the adjusted hazard ratio and the proportion of cases within the vaccination category. RESULTS: Between December 2021, and March 2023, we recorded 187143 SARS-CoV-2 cases, 1728 (0.93%) hospitalizations and 611 (0.33%) deaths. The risk of severe outcomes increased with age, was higher among men and nursing home residents. Compared to unvaccinated adults, VE against hospitalization was 38.8% (95%CI: 28.1%-47.8%) for a complete primary cycle of vaccination, 62.1% (95%CI: 57.0%-66.7%) for one booster, and 71.6% (95%CI: 66.7%-76.2%) for two booster doses. VE against death was respectively 49.5% (95%CI: 30.8%-63.3%), 69.0% (95%CI: 61.2%-75.3%) and 76.2% (95%CI: 68.4%-82.2%). Previous infection was not associated with lower risk of hospitalisation or mortality. The vaccination lowered mortality by 55.8 % (95%CI: 46.3%-62.8%) and reduced hospital admissions by 49.1% (95%CI: 43.4%-54.4%). CONCLUSIONS: Complete vaccination and booster but not previous infection were protective against hospitalization and death. The vaccination program in Luxembourg led to substantial reductions in SARS-CoV-2-related mortality and hospitalizations at the population level.
引用
- Bejko D, Ernst C, Vergison A, et al. High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis. Vaccine. 2024. PMID: 38825555. doi:10.1016/j.vaccine.2024.05.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。